Evidence map›Paper›PMID 39261444›Full record

SynthesisAmerican journal of cardiovascular drugs : drugs, devices, and other interventions2024

The Efficacy and Safety of Levosimendan in Patients with Advanced Heart Failure: An Updated Meta-Analysis of Randomized Controlled Trials.

Ahmed Saad Elsaeidy, Mohamed Abuelazm, Ramy Ghaly, Youssef Soliman, Ahmed Mazen Amin, Mohamed El-Gohary, Salem Elshenawy, Amith Reddy Seri, Basel Abdelazeem, Brijesh Patel and 1 more

Abstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in American journal of cardiovascular drugs : drugs, devices, and other interventions, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Observational
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Ahmed Saad Elsaeidy *Faculty of Medicine, Benha University, Benha, Egypt. AhmedSaadElsaeidy@gmail.com.ORCID http://orcid.org/0000-0002-1643-9750
Mohamed Abuelazm *Faculty of Medicine, Tanta University, Tanta, Egypt.
Ramy GhalyDepartment of Internal Medicine, University of Missouri-Kansas City, Kansas City, USA.
Youssef SolimanFaculty of Medicine, Assiut University, Assiut, Egypt.
Ahmed Mazen AminFaculty of Medicine, Mansoura University, Mansoura, Egypt.
Mohamed El-GoharyDepartment of Internal Medicine, University of Missouri-Kansas City, Kansas City, USA.
Salem ElshenawyFaculty of Medicine, Alexandria University, Alexandria, Egypt.
Amith Reddy SeriDepartment of Internal Medicine, McLaren Health Care/Michigan State University, Flint, MI, USA.
Basel AbdelazeemDepartment of Cardiology, West Virginia University, West Virginia, USA.
Brijesh PatelDepartment of Cardiology, West Virginia University, West Virginia, USA.
Christopher BiancoDepartment of Cardiology, West Virginia University, West Virginia, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIntermittent ambulatory levosimendan administration has been shown in several small randomized controlled trials to benefit patients with advanced heart failure, preventing heart failure rehospitalization and mortality. We aim to investigate the totality of high-quality evidence regarding the efficacy and safety of intermittent levosimendan in advanced heart failure patients.

methodsUp to September 2023, we systematically reviewed the randomized controlled trials indexed in PubMed, Embase Cochrane, SCOPUS, and Web of Science. We used mean difference (MD) to estimate the continuous outcomes, and risk ratio (RR) for the dichotomous outcomes with a 95% confidence interval (CI), using the random-effects model. Ultimately, a trial sequential analysis was employed to enhance the reliability of our findings and Grading of Recommendations Assessment, Development, and Evaluation (GRADE) framework for certainty leveling.

resultsFifteen randomized controlled trials with 1181 patients were included. Intermittent levosimendan was significantly associated with an improved left ventricular ejection fraction compared with  placebo (MD 6.39 [95% CI 3.04-9.73], P = 0.002; I

conclusionIn patients with advanced heart failure, intermittent levosimendan significantly improved left ventricular ejection fraction, brain natriuretic peptide values, and all-cause mortality rate. Levosimendan use is not associated with a change in rehospitalization or event-free survival. REGISTRATION: PROSPERO identifier number (CRD42023487838).

Indexed as

Cardiotonic AgentsHeart FailureRandomized Controlled Trials as TopicSimendanHumansStroke VolumeVentricular Function, LeftCardiotonic AgentsSimendan

Identifiers

PMID39261444
PMCPMC11525400

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.